- Development of Intercell's Streptococcus pneumoniae vaccine supported by PATH VIENNA, April 7 /PRNewswire/ -- Intercell AG (VSE: ICLL) announced today that a Phase I clinical trial with the ...
VIENNA, Austria, Aug. 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine ...
Intercell is a unique platform of industry experts and professionals who mentor people and give them direction on their career. Gurgaon, Haryana, India: Intercell, the first of its kind Virtual Mentor ...
LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...
France's Vivalis is buying Austrian vaccines specialist Intercell in a deal the firms say will result in the "creation of a European biotech leader". France’s Vivalis is buying Austrian vaccines ...
French-owned Vivalis will acquire Austria’s Intercell for about €133 million ($174 million), in a merger intended to create a stronger developer of anti-infective treatments. The merged company, to be ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Intercell jumped 16 per cent after the Austrian biotechnology company announced that it had agreed a ...
Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...
VIENNA (Reuters) - Austrian biotech firm Intercell won a deal to sell shares and rights to its vaccine technology to drugmaker Novartis for 270 million euros ($363 million), pushing its stock to ...
Struggling biotech Intercell isn't giving up on its needless patch system for delivering vaccines. After its vax patch flunked multiple trials last year, the Austria-based firm is on the hunt for new ...
Needlephobes, rejoice: Vaccines may soon be a lot less painful. A needle-free vaccination method is being developed by Intercell USA (which, before its acquisition by Austria’s Intercell AG in August, ...
Intercell AG has announced that the company’s Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011. At the same time, Gerd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results